Founded in 2012 as a spinout from the University of Cambridge, the company is led by eminent researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who discovered the pivotal role of the TET enzymes and 5hmC in development and disease. Having garnered a $88.00M Series D investment on 02 November 2021, Cambridge Epigenetix has attracted significant support from high-profile investors such as GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital, and the University of Cambridge. Its focus on delivering groundbreaking advancements in biotechnology and healthcare positions Cambridge Epigenetix as a formidable player in the industry, with significant potential for continued growth and impact.
Cambridge Epigenetix
Innovating healthcare with a simple blood test for early detection of colorectal cancer and other tumors.
General Information
Get notified when Cambridge Epigenetix moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Cambridge Epigenetix
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Biotechnology
About Cambridge Epigenetix
Taxonomy: clinical epigenetics, DNA modification, biomarker discovery, diagnostic assays, precision medicine, colorectal cancer screening, tumor detection, biotechnology startup, venture capital, early cancer detection, University of Cambridge spin-off, 5-hydroxymethylcytosine (5hmC), Solexa sequencing, investor-backed
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series D | •••••• | 6 |
|
02 Nov 2021 |
| Convertible Note | •••••• | - | 24 Nov 2020 | |
| Series C | •••••• | 4 |
|
03 Sep 2018 |
| Series B | •••••• | - | 14 Mar 2016 | |
| Series A | •••••• | - | 29 Oct 2014 |
Cambridge Epigenetix Alternatives & Competitors
To give everyone diagnosed with cancer their best chance to become cancer free
GnuBIO Inc is a genomics company based in Cambridge, MA. We are pioneers in the field of DNA sequenc...
Pioneering Life-Saving Cancer Detection with Advanced Liquid Biopsy Solutions
FAQ About Cambridge Epigenetix
Don't just browse. Track.
Signal Tracker monitors Cambridge Epigenetix and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.